Similarly to CD5 and CD7 molecules, CD3 was firstly evaluated as a therapeutic target in patients with T-cell lymphoma in studies using immunotoxin-loaded anti-CD3ε mAbs [152]. This evidence concerns the gene CD7 and T-cell non-Hodgkin lymphoma.